載入中
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
前收盤價
US$14.89
−US$0.11 · -0.73%
盤中時間採用ET。市場資料可能有所延遲。
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
日內區間
目前US$14.89
52週區間
目前US$14.89
盤中時間採用ET。市場資料可能有所延遲。
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
日內區間
目前US$14.89
52週區間
目前US$14.89
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
